Hypomelanotic Disorder Clinical Trials

Find Hypomelanotic Disorder Clinical Trials Near You

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period

Status: Recruiting
Location: See all (83) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:

• Signed informed consent must be obtained prior to participation in the study

• Male or female as assigned at birth ≥ 18 years of age at the time of screening

• Individuals with a diagnosis of non-segmental vitiligo and confirmation of diagnosis through physical examination by the investigator

• Non-segmental vitiligo, as assessed at screening, as

• ≥ 0.5% Body Surface Area (BSA) on the face and F-VASI score ≥ 0.5

• ≥ 3% BSA on non-facial areas (minimum of 3% should be calculated in addition to hands and feet) and T-VASI score = 3 to 60

Locations
United States
Alabama
Cahaba Derm and skin hlth ctr 27
RECRUITING
Birmingham
California
First OC Dermatology
RECRUITING
Fountain Valley
MedDerm Associates
RECRUITING
San Diego
Clinical Trials Research Institute
RECRUITING
Thousand Oaks
Florida
Encore Medical Research
RECRUITING
Hollywood
Mayo Clinic Jacksonville
RECRUITING
Jacksonville
Miami Derm and Laser Institute
RECRUITING
Miami
Global Clinical Professionals
RECRUITING
St. Petersburg
Illinois
Endeavor Health
RECRUITING
Glenview
Indiana
Dawes Fretzin Clinical Rea Group
RECRUITING
Indianapolis
Maryland
DermAssociates LLC
RECRUITING
Rockville
Michigan
Uni Of Michigan Health System
RECRUITING
Ann Arbor
Hamzavi Dermatology
RECRUITING
Fort Gratiot
Revival Research Institute
RECRUITING
Troy
Nebraska
Skin Specialists PC
RECRUITING
Omaha
Nevada
Las Vegas Dermatology
RECRUITING
Las Vegas
New York
Equity Medical
RECRUITING
The Bronx
Oregon
Oregon Medical Research Center
RECRUITING
Portland
Tennessee
International Clinical Research Tennessee LCC
RECRUITING
Murfreesboro
Texas
Bellaire Dermatology Associates
RECRUITING
Bellaire
Center for Clinical Studies
RECRUITING
Houston
Austin Inst for Clinical Research
RECRUITING
Pflugerville
ACRC Trials
RECRUITING
Plano
Virginia
Virginia Clinical Research
RECRUITING
Norfolk
Other Locations
Argentina
Novartis Investigative Site
RECRUITING
Buenos Aires
Novartis Investigative Site
RECRUITING
Caba
Novartis Investigative Site
RECRUITING
Caba
Novartis Investigative Site
RECRUITING
Rosario
Novartis Investigative Site
RECRUITING
San Miguel De Tucumán
Australia
Novartis Investigative Site
RECRUITING
Melbourne
Novartis Investigative Site
RECRUITING
Sydney
Novartis Investigative Site
RECRUITING
Waitara
Canada
Novartis Investigative Site
RECRUITING
Calgary
Novartis Investigative Site
RECRUITING
Mississauga
Novartis Investigative Site
RECRUITING
Newmarket
Novartis Investigative Site
RECRUITING
Québec
Novartis Investigative Site
RECRUITING
Toronto
Novartis Investigative Site
RECRUITING
Winnipeg
China
Novartis Investigative Site
RECRUITING
Beijing
Novartis Investigative Site
RECRUITING
Guangzhou
Novartis Investigative Site
RECRUITING
Shanghai
Novartis Investigative Site
RECRUITING
Wuhan
France
Novartis Investigative Site
RECRUITING
Bordeaux
Novartis Investigative Site
RECRUITING
Brest
Novartis Investigative Site
RECRUITING
Créteil
Novartis Investigative Site
RECRUITING
Nice
Novartis Investigative Site
RECRUITING
Reims
Novartis Investigative Site
RECRUITING
Rouen
Novartis Investigative Site
RECRUITING
Toulouse
Germany
Novartis Investigative Site
RECRUITING
Bad Bentheim
Novartis Investigative Site
RECRUITING
Bielefeld
Novartis Investigative Site
RECRUITING
Hamburg
Novartis Investigative Site
RECRUITING
Hanover
Novartis Investigative Site
RECRUITING
Lübeck
Novartis Investigative Site
RECRUITING
Munich
Novartis Investigative Site
RECRUITING
Münster
Novartis Investigative Site
RECRUITING
Tübingen
India
Novartis Investigative Site
RECRUITING
Ahmedabad
Novartis Investigative Site
RECRUITING
Bangalore
Novartis Investigative Site
RECRUITING
Belagavi
Novartis Investigative Site
RECRUITING
Mysore
Novartis Investigative Site
RECRUITING
Nashik
Novartis Investigative Site
RECRUITING
Patna
Italy
Novartis Investigative Site
RECRUITING
Ancona
Novartis Investigative Site
RECRUITING
Cona
Novartis Investigative Site
RECRUITING
Milan
Novartis Investigative Site
RECRUITING
Rozzano
Japan
Novartis Investigative Site
RECRUITING
Kofu
Novartis Investigative Site
RECRUITING
Nagoya
Novartis Investigative Site
RECRUITING
Nagoya
Novartis Investigative Site
RECRUITING
Niigata
Novartis Investigative Site
RECRUITING
Shinjuku Ku
Novartis Investigative Site
RECRUITING
Urayasu
Netherlands
Novartis Investigative Site
RECRUITING
Amsterdam
Novartis Investigative Site
RECRUITING
Rotterdam
Spain
Novartis Investigative Site
RECRUITING
Barcelona
Novartis Investigative Site
RECRUITING
Córdoba
Novartis Investigative Site
RECRUITING
Granada
Novartis Investigative Site
RECRUITING
Madrid
Novartis Investigative Site
RECRUITING
Madrid
Novartis Investigative Site
RECRUITING
Pontevedra
Novartis Investigative Site
RECRUITING
Santiago De Compostela
Novartis Investigative Site
RECRUITING
Seville
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
1-888-669-6682
Backup
Novartis Pharmaceuticals
+41613241111
Time Frame
Start Date: 2026-03-09
Estimated Completion Date: 2030-01-28
Participants
Target number of participants: 210
Treatments
Experimental: GIA632 Arm 1
GIA632 will be administered during the 48-week core period.
Experimental: GIA632 Arm 2
GIA632 will be administered during the 48-week core period.
Experimental: GIA632 Arm 3
GIA632 will be administered during the 48-week core period.
Experimental: GIA632 Arm 4
GIA632 will be administered during the 48-week core period.
Placebo_comparator: Placebo
Placebo will be administered during the 48-week core period.
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals

This content was sourced from clinicaltrials.gov